EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FORECAST 2019-2027

  • You are here:
  • Home
  • Reports
  • EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FORECAST 2019-2027

EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FORECAST 2019-2027

The Europe market for active pharmaceutical ingredients is on an exceptional upsurge in recent years since the region includes the developed countries in the likes of Germany, France, UK, etc. The regional market is expected to have an escalated growth, quantified by Inkwood Research as per the market analysis, to be around 5.75% CAGR by the end of 2027.

EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FORECAST 2019-2027

Europe Active Pharmaceutical Ingredients Market by Types (Generic Apis, Innovative Apis) by Manufacturers (Captive Apis, Merchant Apis) by Synthesis (Biotech, Synthetic) by Application (Cardiovascular Disease, Oncology, Cns and Neurological Disorders, Orthopedic Disorders, Endocrinology, Pulmonology, Gastrointestinal Disorders, Nephrology, Ophthalmology, Other Application) by Geography.

Request free sample

The pharmaceutical drug industry across the world is growing by leaps and bounds at present and is currently valued in billions approximately. The coveted companies in the market design the required drugs which predominantly contains the carrier substances and the active chemical substances that work in treating the condition known as the ‘active pharmaceutical ingredients’ or API in short.

The Europe market for active pharmaceutical ingredients is on an exceptional upsurge in recent years since the region includes the developed countries in the likes of Germany, France, UK, etc. The regional market is expected to have an escalated growth, quantified by Inkwood Research as per the market analysis, to be around 5.75% CAGR by the end of 2027. The forecasting period is considered to be from 2019 to 2027, and 2018 is considered to be the base year for the market analysis.

The major economies that influence the market growth for APIs in the Europe region are the United Kingdom, France, Germany, Italy, Spain and the remaining countries collectively constituting the Rest of Europe regional segment.

In the United Kingdom, the presence of highly established healthcare infrastructure coupled with the high rate of cancer prevalence among the patient pool are the key driving factors for the API market. According to the Cancer Research United Kingdom, there are more than XX thousands of new cancer cases in the UK every year, which has escalated the adoption of the cancer drugs turbulently in the country.

The increasing prevalence of cardiovascular diseases, neurological diseases, and other lifestyle diseases coupled with growing investments in genomics and proteomics are expected to drive the growth of the European market.

Novartis, Cipla, Lonza Group AG, Mylan N.V., Sun Pharmaceuticals Industries, Ltd., Abbvie, Inc., Bristol-Myers Squibb, Merck & Co., Inc., Teva Pharmaceutical Industries, Ltd., Boehringer Ingelheim GmbH, Eli Lilly and Company, Albemarle Corporation, Dr. Reddy’s Laboratories, Aurobindo Pharma, and Bayer AG are the major companies which have been profiled in the report.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP-DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • INNOVATIVE APIS HOLDS THE LARGEST MARKET SHARE IN TERMS OF ACTIVE PHARMACEUTICAL INGREDIENTS TYPE
      • MERCHANT APIS ARE THE FASTEST GROWING MANUFACTURERS
      • BIOTECH IS THE FASTEST GROWING SYNTHESIS SEGMENT
      • ONCOLOGY IS THE MAJORLY USED APPLICATION
  1. MARKET DYNAMICS
    • MARKET SCOPE & DEFINITION
    • MARKET DRIVERS
      • GROWING GERIATRIC POPULATION
      • GROWING PREVALENCE OF INFECTIOUS DISEASES AND HOSPITAL ACQUIRED INFECTIONS
      • INCREASING INCIDENCE OF AGE-RELATED DISEASES
    • MARKET RESTRAINTS
      • HIGH COST OF INVESTMENT AND PRODUCTION COST
      • AGGRESSIVE COMPETITION AMONG API MANUFACTURERS
    • MARKET OPPORTUNITIES
      • GAINING POPULARITY FOR TARGETED THERAPY
      • GROWING PREFERENCE FOR OUTSOURCING APIS
      • IMPLEMENTING MEASURES AGAINST COUNTERFEIT DRUGS
    • MARKET CHALLENGES
      • STRINGENT GOVERNMENT REGULATIONS
      • AVAILABILITY OF COUNTERFEIT PRODUCTS
  1. MARKET BY TYPES
    • GENERIC APIS
    • INNOVATIVE APIS
  2. MARKET BY MANUFACTURERS
    • CAPTIVE APIS
    • MERCHANT APIS
  3. MARKET BY SYNTHESIS
    • BIOTECH
      • MONOCLONAL ANTIBODIES
      • RECOMBINANT PROTEINS
      • VACCINES
    • SYNTHETIC
  4. MARKET BY APPLICATION
    • CARDIOVASCULAR DISEASE
    • ONCOLOGY
    • CNS AND NEUROLOGICAL DISORDERS
    • ORTHOPEDIC DISORDERS
    • ENDOCRINOLOGY
    • PULMONOLOGY
    • GASTROINTESTINAL DISORDERS
    • NEPHROLOGY
    • OPHTHALMOLOGY
    • OTHER APPLICATION
  5. KEY ANALYTICS
    • PORTER’S FIVE FORCES MODEL
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTE
      • BARGAINING POWER OF BUYERS
      • BARGAINING POWER OF SUPPLIERS
      • THREAT OF COMPETITIVE RIVALRY
    • PESTEL ANALYSIS
    • SUPPLY CHAIN ANALYSIS
    • OPPORTUNITY MATRIX
  6. GEOGRAPHICAL ANALYSIS
    • EUROPE
      • THE UNITED KINGDOM
      • GERMANY
      • FRANCE
      • ITALY
      • SPAIN
      • REST OF EUROPE
  1. COMPETITIVE LANDSCAPE
    • MARKET POSITION ANALYSIS
    • COMPANY PROFILES
      • ABBVIE, INC.
      • ALBEMARLE CORPORATION
      • AUROBINDO PHARMA
      • BAYER AG
      • BOEHRINGER INGELHEIM GMBH
      • BRISTOL-MYERS SQUIBB
      • CIPLA
      • REDDY’S LABORATORIES
      • ELI LILLY AND COMPANY
      • LONZA GROUP AG
      • MERCK & CO., INC.
      • MYLAN N.V.
      • NOVARTIS
      • SUN PHARMACEUTICALS INDUSTRIES, LTD.
      • TEVA PHARMACEUTICAL INDUSTRIES LTD.

TABLE LIST

TABLE 1        EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)

TABLE 2        EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPES 2019-2027 ($ MILLION)

TABLE 3        EUROPE GENERIC APIS MARKET 2019-2027 ($ MILLION)

TABLE 4        EUROPE INNOVATIVE APIS MARKET 2019-2027 ($ MILLION)

TABLE 5        EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURERS 2019-2027 ($ MILLION)

TABLE 6        EUROPE CAPTIVE APIS MARKET 2019-2027 ($ MILLION)

TABLE 7        EUROPE MERCHANT APIS MARKET 2019-2027 ($ MILLION)

TABLE 8        EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY SYNTHESIS 2019-2027 ($ MILLION)

TABLE 9        EUROPE BIOTECH MARKET 2019-2027 ($ MILLION)

TABLE 10      EUROPE BIOTECH MARKET BY TYPES 2019-2027 ($ MILLION)

TABLE 11      EUROPE MONOCLONAL ANTIBODIES MARKET 2019-2027 ($ MILLION)

TABLE 12      EUROPE RECOMBINANT PROTEINS MARKET 2019-2027 ($ MILLION)

TABLE 13      EUROPE VACCINES MARKET 2019-2027 ($ MILLION)

TABLE 14      EUROPE SYNTHETIC MARKET 2019-2027 ($ MILLION)

TABLE 15      EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY APPLICATION 2019-2027 ($ MILLION)

TABLE 16      EUROPE CARDIOVASCULAR DISEASE MARKET 2019-2027 ($ MILLION)

TABLE 17      EUROPE ONCOLOGY MARKET 2019-2027 ($ MILLION)

TABLE 18      EUROPE CNS AND NEUROLOGICAL DISORDERS MARKET 2019-2027 ($ MILLION)

TABLE 19      EUROPE ORTHOPEDIC DISORDERS MARKET 2019-2027 ($ MILLION)

TABLE 20      EUROPE ENDOCRINOLOGY MARKET 2019-2027 ($ MILLION)

TABLE 21      EUROPE PULMONOLOGY MARKET 2019-2027 ($ MILLION)

TABLE 22      EUROPE GASTROINTESTINAL DISORDERS MARKET 2019-2027 ($ MILLION)

TABLE 23      EUROPE NEPHROLOGY MARKET 2019-2027 ($ MILLION)

TABLE 24      EUROPE OPHTHALMOLOGY MARKET 2019-2027 ($ MILLION)

TABLE 25      EUROPE OTHER APPLICATION MARKET 2019-2027 ($ MILLION)

TABLE 26      EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY COUNTRY 2019-2027 ($ MILLION)

TABLE 27      ACTIVE PHARMACEUTICAL INGREDIENTS COMPANY MARKET POSITION ANALYSIS 2017

 

FIGURE LIST 

FIGURE 1      EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)

FIGURE 2      EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY TYPES 2018 & 2027 (%)

FIGURE 3      EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GENERIC APIS 2019-2027 ($ MILLION)

FIGURE 4      EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY INNOVATIVE APIS 2019-2027 ($ MILLION)

FIGURE 5      EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY MANUFACTURERS 2018 & 2027 (%)

FIGURE 6      EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CAPTIVE APIS 2019-2027 ($ MILLION)

FIGURE 7      EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MERCHANT APIS 2019-2027 ($ MILLION)

FIGURE 8      EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY SYNTHESIS 2017 & 2027 (%)

FIGURE 9      EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BIOTECH 2019-2027 ($ MILLION)

FIGURE 10   EUROPE BIOTECH MARKET BY MONOCLONAL ANTIBODIES 2019-2027 ($ MILLION)

FIGURE 11   EUROPE BIOTECH MARKET BY RECOMBINANT PROTEINS 2019-2027 ($ MILLION)

FIGURE 12   EUROPE BIOTECH MARKET BY VACCINES 2019-2027 ($ MILLION)

FIGURE 13   EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY SYNTHETIC 2019-2027 ($ MILLION)

FIGURE 14   EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY APPLICATION 2018 & 2027 (%)

FIGURE 15   EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CARDIOVASCULAR DISEASE 2019-2027 ($ MILLION)

FIGURE 16   EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ONCOLOGY 2019-2027 ($ MILLION)

FIGURE 17   EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CNS AND NEUROLOGICAL DISORDERS 2019-2027 ($ MILLION)

FIGURE 18   EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ORTHOPEDIC DISORDERS 2019-2027 ($ MILLION)

FIGURE 19   EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ENDOCRINOLOGY 2019-2027 ($ MILLION)

FIGURE 20   EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY PULMONOLOGY 2019-2027 ($ MILLION)

FIGURE 21   EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GASTROINTESTINAL DISORDERS 2019-2027 ($ MILLION)

FIGURE 22   EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY NEPHROLOGY 2019-2027 ($ MILLION)

FIGURE 23   EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY OPHTHALMOLOGY 2019-2027 ($ MILLION)

FIGURE 24   EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY OTHER APPLICATION 2019-2027 ($ MILLION)

FIGURE 25   PORTER’S FIVE FORCE MODEL

FIGURE 26   THE UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)

FIGURE 27   GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)

FIGURE 28   FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)

FIGURE 29   ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)

FIGURE 30   SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)

FIGURE 31   REST OF EUROPE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)

 

  1. GEOGRAPHICAL ANALYSIS
    • EUROPE
      • THE UNITED KINGDOM
      • GERMANY
      • FRANCE
      • ITALY
      • SPAIN
      • REST OF EUROPE
  1. MARKET BY TYPES
    • GENERIC APIS
    • INNOVATIVE APIS
  2. MARKET BY MANUFACTURERS
    • CAPTIVE APIS
    • MERCHANT APIS
  3. MARKET BY SYNTHESIS
    • BIOTECH
      • MONOCLONAL ANTIBODIES
      • RECOMBINANT PROTEINS
      • VACCINES
    • SYNTHETIC
  4. MARKET BY APPLICATION
    • CARDIOVASCULAR DISEASE
    • ONCOLOGY
    • CNS AND NEUROLOGICAL DISORDERS
    • ORTHOPEDIC DISORDERS
    • ENDOCRINOLOGY
    • PULMONOLOGY
    • GASTROINTESTINAL DISORDERS
    • NEPHROLOGY
    • OPHTHALMOLOGY
    • OTHER APPLICATION

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now